scholarly journals Once again about the clinical efficacy and safety of sartans

2014 ◽  
Vol 11 (4) ◽  
pp. 84-86
Author(s):  
Ye S Minina ◽  
B R Khadzhieva
Keyword(s):  
Angiotensin Ii ◽  
Arterial Hypertension ◽  
Clinical Efficacy ◽  
Angiotensin Receptor Blockers ◽  
Clinical Use ◽  
Angiotensin Receptor ◽  
Efficacy And Safety ◽  
Receptor Blockers

Sartans are safety and effective class of anti-hypertensives nowadays. Sartans are the most effective inpatients suffering from arterial hypertension. Their efficiency is determined by the association of Angiotensin II type 1 receptor. Candesartan and azilsartan are themost powerful and approved angiotensin receptor blockers. Candesartan in comparison with azilsartan has wide proposed spectrum of clinical use. Azilsartan is indicated for the treatment of arterial hypertension. In terms of efficiency and safety we showed these sartans.

scholarly journals Comparative analysis of the angiotensin receptors blockers and angiotensin-converting enzyme inhibitors in the treatment of arterial hypertension (review of literature)

2020 ◽  
Vol 43 (4) ◽  
pp. 490-497
Author(s):  
Mariya S. Matveenko ◽  
◽  
Keyword(s):  
Angiotensin Ii ◽  
Angiotensin Converting Enzyme ◽  
Arterial Hypertension ◽  
Enzyme Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Receptor Blockers

Cardiovascular diseases are still one of the main causes of death and disability among the adult population, the search for optimal pharmacotherapy of arterial hypertension remains an urgent task. The renin-angiotensin-aldosterone system (RAAS) plays a direct role in the pathophysiology of arterial hypertension, being responsible for regulating fluid volume and maintaining water - salt balance. RAAS is also responsible for the processes of tissue growth and differentiation, apoptosis, and affects the synthesis of many neurohumoral factors. By increasing the activity of the RAAS angiotensin II contributes to vasoconstriction, increased secretion of aldosterone and the activity of the sympathetic nervous system, which in turn leads to the development and progression of hypertension. Angiotensin–II receptor blockers (ARBs) block the AT1 subtype receptors of the same name, which is accompanied by vasodilation, a decrease in the secretion of vasopressin and aldosterone. RAAS blockade is an effective modern reliable way to control blood pressure, as well as prevent related complications. angiotensin converting enzyme inhibitors and angiotensin receptor blockers have similar hypotensive effects and a high safety profile. Due to differences in the mechanism of action, when taking angiotensin receptor blockers, the frequency of undesirable side effects is recorded less, and, accordingly, adherence to treatment is greater. One of the modern angiotensin receptor blockers, olmesartan in various studies has demonstrated its superiority over angiotensin-converting enzyme inhibitors (ramipril and perindopril) in the treatment of arterial hypertension. Olmesartan has proven itself both in monotherapy and in combination with a dihydropyridine calcium channel blocker or a thiazide diuretic.

scholarly journals Synthetic nanobodies as angiotensin receptor blockers

2020 ◽  
Vol 117 (33) ◽  
pp. 20284-20291
Author(s):  
Conor McMahon ◽  
Dean P. Staus ◽  
Laura M. Wingler ◽  
Jialu Wang ◽  
Meredith A. Skiba ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Angiotensin Receptor Blockers ◽  
Antihypertensive Activity ◽  
Angiotensin Receptor ◽  
Ligand Binding Sites ◽  
Antibody Discovery ◽  
Receptor Blockers ◽  
Selection Methodology ◽  
G Protein Coupled

There is considerable interest in developing antibodies as functional modulators of G protein-coupled receptor (GPCR) signaling for both therapeutic and research applications. However, there are few antibody ligands targeting GPCRs outside of the chemokine receptor group. GPCRs are challenging targets for conventional antibody discovery methods, as many are highly conserved across species, are biochemically unstable upon purification, and possess deeply buried ligand-binding sites. Here, we describe a selection methodology to enrich for functionally modulatory antibodies using a yeast-displayed library of synthetic camelid antibody fragments called “nanobodies.” Using this platform, we discovered multiple nanobodies that act as antagonists of the angiotensin II type 1 receptor (AT1R). Following angiotensin II infusion in mice, we found that an affinity matured nanobody antagonist has comparable antihypertensive activity to the angiotensin receptor blocker (ARB) losartan. The unique pharmacology and restricted biodistribution of nanobody antagonists may provide a path for treating hypertensive disorders when small-molecule drugs targeting the AT1R are contraindicated, for example, in pregnancy.

scholarly journals Blocker, angiotensin II receptor olmesartan to interrupt cardiovascular continuum: vesselsand cardioprotective, anti-atherosclerotic and metabolic pleiotropic effects (part 2)

2015 ◽  
Vol 6 (1) ◽  
pp. 65-74
Author(s):  
M. G Bubnova
Keyword(s):  
Angiotensin Ii ◽  
Clinical Efficacy ◽  
Clinical Studies ◽  
Angiotensin Receptor Blockers ◽  
Olmesartan Medoxomil ◽  
Angiotensin Receptor ◽  
Angiotensin Ii Receptor ◽  
Wide Range ◽  
Receptor Blockers ◽  
Cardiovascular Continuum

The article provides an overview of pleiotropic activity and clinical efficacy of one of the representatives of the class of angiotensin receptor blockers II - olmesartan medoxomil. Analyzed is a wide range of established in experimental and clinical studies and vasoconstriction, cardioprotective, anti-atherogenic, anti-inflammatory and other effects of olmesartan medoxomil. Given clinical studies evaluating anti-atherosclerotic effects of this drug.

Sign in / Sign up

Export Citation Format

Share Document